HC Wainwright Reiterates “Buy” Rating for uniQure (NASDAQ:QURE)

HC Wainwright restated their buy rating on shares of uniQure (NASDAQ:QURE) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $25.00 price objective on the biotechnology company’s stock.

Separately, Mizuho lowered their price target on uniQure from $7.00 to $6.00 and set a neutral rating for the company in a report on Wednesday, May 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, uniQure currently has a consensus rating of Moderate Buy and an average target price of $23.00.

uniQure Stock Down 12.0 %

Shares of QURE opened at $8.91 on Tuesday. The company has a quick ratio of 9.27, a current ratio of 9.39 and a debt-to-equity ratio of 0.70. The stock’s fifty day simple moving average is $5.00 and its 200 day simple moving average is $5.37. uniQure has a twelve month low of $3.73 and a twelve month high of $11.59.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.05). uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. The company had revenue of $8.49 million during the quarter, compared to analyst estimates of $2.58 million. Equities research analysts expect that uniQure will post -4.45 earnings per share for the current year.

Institutional Trading of uniQure

Several large investors have recently modified their holdings of the business. Raymond James & Associates grew its stake in shares of uniQure by 6.4% during the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after acquiring an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 58.5% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 3,664 shares in the last quarter. Harbor Capital Advisors Inc. grew its stake in shares of uniQure by 21.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 5,389 shares in the last quarter. Pale Fire Capital SE grew its stake in shares of uniQure by 9.2% during the fourth quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock valued at $444,000 after acquiring an additional 5,500 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in uniQure in the fourth quarter worth about $86,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.